Loading
companiesCompany
Fennec Pharmaceuticals
Fennec Pharmaceuticals is the North Carolina company behind Pedmark, the sodium thiosulfate infusion given after cisplatin to protect children's hearing from the chemotherapy.
Also called: Adherex TechnologiesFennec Pharmaceuticals Inc.NASDAQ:FENC
Overview
Fennec Pharmaceuticals, formerly Adherex Technologies, developed Pedmark (sodium thiosulfate) as an otoprotectant. Given six hours after each cisplatin dose, it neutralises the platinum that damages inner-ear hair cells; the SIOPEL 6 and ACCL0431 trials showed roughly halved rates of hearing loss in children with localised solid tumours. The FDA approved Pedmark in September 2022 for patients aged one month and older, and the European Union approved it as Pedmarqsi in 2023.
Headquarters
Research Triangle Park, North Carolina, US
Scorecard
All companies#218of 1244 companies, score 24
- approved products +6
- modalities +2
- regions +3
- registry trials +13
1 approved, 0 in phase 3, 0 earlier, 0 targets, 43 registry studies. Formula on the scorecards page.
Type
Large pharma · NASDAQ:FENC
Stage
Public
Website
ApprovedSmall-molecule chemoprotectant
Sodium thiosulfate (otoprotectant) · Pedmark
An old antidote proven in two paediatric trials to halve permanent hearing loss from cisplatin, and approved in 2022 as the first drug to prevent a chemotherapy side effect in children.
drugs
ApprovedSmall-molecule chemoprotectant
Sodium thiosulfate (otoprotectant) · Pedmark